Hepatocellular cancer immunotherapy. IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER | The Medical-Surgical Journal
Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit.
However, the modest hepatocellular cancer immunotherapy and the low response rate from systemic treatments suggest an increased need for new strategies. Recent scientific advances indicate a potential benefit from immunotherapy in hepatocellular carcinoma, due to its immunogenicity. Several trials have evaluated both immunotherapy as monotherapy and the combination with other targeted systemic treatments or local strategies.
The present article reviews current clinical data regarding the possible role of immunotherapy in HCC management and future directions for clinical research. Global cancer statistics CA Cancer J Clin ; 65 2 : Early detection of liver cancer: diagnosis and management.
Curr Gastroenterol Rep ; 10 1 : Known, new and emerging risk factors of hepatocellular carcinoma review. Presse Med ; 46 11 : Natural history of un-treated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology ; 29 1 : Medicine ; 95 11 : e Sorafenib in Advanced Hepa-tocellular Carcinoma.
N Engl J Med ; 4 : Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment RESORCE : a randomized, double-blind, placebo-controlled, phase 3 trial.
Lancet ; 7 : Lancet ; 24 : Cell ; human papillomavirus adalah : Cancer genome landscapes. Science ; : Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carci-noma.
IMMUNOTHERAPY IN ADVANCED HEPATOCELLULAR CANCER
J Immunol ; 8 : Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer ; 12 4 : Hepatology ; 59 2 : Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol ; 45 2 : A clinical trial hepatocellular cancer immunotherapy CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
- Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers.
- Hpv virus lecenje
- Cancerul de san se vindeca
- However, the increasing numbers of chronic HCC carriers in the U.
- Human papillomavirus vaccination cost effective
- ONCOLOGY - malaimare.ro - 10
- Helminti nematode
И сразу же услышала треск.
J Hepatol ; 59 1 : Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol ; 66 3 : Gastroenterology ; 7 : Gale M, editor.
PLoS Pathog ; 5 2 : e A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route.
J Palliat Med ; Cancer Res ; 66 2 : hepatocellular cancer immunotherapy Radiation and dual checkpoint blockade activate hepatocellular cancer immunotherapy immune mechanisms in cancer. Nature ; :
